Barclays raised the firm’s price target on Stryker to $402 from $374 and keeps an Overweight rating on the shares. The company delivered another strong quarter, raising organic sales growth guidance to 9%-10% and earnings by a touch more than the Q2 beat, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: